Development of Glucagon-Like Peptide-1-Based Pharmaceuticals as Therapeutic Agents for the Treatment of Diabetes

E-ISSN： 1873-4286|7|14|1399-1412

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.7, Iss.14, 2001-09, pp. : 1399-1412

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Glucagon-Like Peptide-1 Synthetic Analogs: New Therapeutic Agents for Use in the Treatment of Diabetes Mellitus

Current Medicinal Chemistry, Vol. 10, Iss. 22, 2003-11 ,pp. : 2471-2483

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment of Type 2 diabetes mellitus based on glucagon-like peptide-1

By Holst J.J.

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 9, 1999-09 ,pp. : 1409-1415

Informa Healthcare

Access to resources Recommend Favorite

Glucagon-like Peptide-1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents

By Gallwitz Baptist

Drugs, Vol. 71, Iss. 13, 2011-09 ,pp. : 1675-1688

Adis International

Access to resources Recommend Favorite

Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes

Current Pharmaceutical Design, Vol. 17, Iss. 38, 2011-01 ,pp. : 4379-4385

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus

Current Clinical Pharmacology, Vol. 12, Iss. 4, 2018-04 ,pp. : 202-209

Bentham Science Publishers

Access to resources Recommend Favorite